Melanie Whittington: Why Are Drugs So Expensive?

Christopher Locher: Why Vaccine Innovation Matters More Than Ever

In this episode of the Vital Health Podcast, host Duane Schulthess [https://www.linkedin.com/in/duane-schulthess-66ba39b7/] speaks with Christopher Locher [https://www.linkedin.com/in/christopher-locher-biotech/], Chief Executive Officer at Versatope Therapeutics [https://www.linkedin.com/company/versatope/], about the current landscape for vaccine manufacturers and innovators. Their conversation covers vaccine platform development, financing challenges for infectious disease companies, policy and regulatory uncertainty, the public health implications of changes to childhood immunization schedules, and the steps needed to rebuild trust in vaccination. Key Topics: * Vaccine Platform Innovation: Nanoparticle technology, universal influenza vaccine development, multispecific targeting, infectious disease, and oncology applications. * Financing Challenges: Venture capital headwinds, NIH support, clinical development costs, grant cancellations, and startup survival pressures. * Policy Uncertainty: Changes to childhood immunization schedules, liability debates, academic licensing concerns, royalty proposals, and the biotech investment climate. * Public Health Risks: Vaccine access, childhood disease vulnerability, antimicrobial resistance, influenza complications, and consequences of fragmented immunization policy. * Trust Rebuilding: COVID backlash, transparency concerns, anti-science sentiment, provider-patient communication, rebuilding confidence in vaccines. Opinions expressed are those of the speakers. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Melanie Whittington: Why Are Drugs So Expensive?

In this episode of the Vital Health Podcast, host Duane Schulthess [https://www.linkedin.com/in/duane-schulthess-66ba39b7/] speaks with Melanie Whittington [https://www.linkedin.com/in/melanie-whittington/], Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center [https://www.linkedin.com/company/cevr/]. They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem. Key Topics * Market Modeling: Hypothetical models versus real-world pricing dynamics, patent cliffs. * Pricing Policy: IRA, MFN, market-based pricing scrutiny, communicating why prices are "worth it". * Innovation Incentives: Private capital risk, oncology small molecules, policy-driven pipeline shifts. * Value Framework Limits: QALY concerns, rule-versus-tool debates, GRACE, broader treatment impacts. * Transparency and Outlook: Net price opacity, PBM negotiations, generics and biosimilars, the next innovation cycle. Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

VT's Grumpies and Lady Discuss the U.S. Biotech Policy Landscape

Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/ [https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/] In this episode of the Vital Health Podcast, host Duane Schulthess [https://www.linkedin.com/in/duane-schulthess-66ba39b7/] speaks with two Vital Transformation [https://www.linkedin.com/company/vital-transformation/] colleagues on biopharma pricing policy, market access, and innovation risk: * Gwen O'Loughlin [https://www.linkedin.com/in/gwen-o-loughlin-8792003a9/]: Research Partner at Vital Transformation [https://www.linkedin.com/company/vital-transformation/] * Harry Bowen [https://www.linkedin.com/in/harry-p-bowen-10761b31/]: Consulting Economist at Vital Transformation [https://www.linkedin.com/company/vital-transformation/] They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation. Key Topics: * MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty. * Effects of IRA on Trials: Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials. * Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns. * 340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure. * Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns. Opinions expressed are those of the speakers. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Tim Scott: MFN Pricing, Venture Risk, and the Future of California Biotech

In this episode of the Vital Health Podcast, host Duane Schulthess [https://www.linkedin.com/in/duane-schulthess-66ba39b7/] speaks with Tim Scott [https://www.linkedin.com/in/tim-scott-501631/], President & CEO of Biocom California [https://www.linkedin.com/company/biocom-california/], a biopharma executive with more than two decades of experience, including spinning out companies from UC San Diego and leading firms acquired by BioMarin and Novartis, to discuss how California’s life sciences ecosystem became a global innovation engine, why the state’s research and venture networks matter, and how policy headwinds such as the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) reference pricing reshape investment, rare disease development, and competition with Europe and China. Key Topics: * Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California. * Innovation Network: University and research density, regional clusters, talent, and collaboration effects. * Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity. * MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback. * Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness. Opinions expressed are those of the speakers. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Mark Rohrbaugh & Gwen O’Loughlin: Drug Patents, March-In Rights, and NIH Technology Transfer

In this episode of the Vital Health Podcast, host Duane Schulthess [https://www.linkedin.com/in/duane-schulthess-66ba39b7/] examines how NIH-funded research fits into the U.S. innovation and IP ecosystem, and why today’s political rhetoric about “government-developed drugs” often misses how commercialization actually happens. Featuring expert perspectives on NIH technology transfer and drug IP from: * Mark Rohrbaugh [https://www.linkedin.com/in/mark-l-rohrbaugh-9462a57/]: Former Director of Technology Transfer and Innovation Policy at the National Institutes of Health (NIH) [https://www.linkedin.com/company/national-institutes-of-health/], IP Consultant at Vital Transformation [https://www.linkedin.com/company/vital-transformation/] * Gwen O’Loughlin [https://www.linkedin.com/in/gwen-o-loughlin-8792003a9/]: Research Partner at Vital Transformation [https://www.linkedin.com/company/vital-transformation/] They discuss how the Bayh-Dole Act shaped university tech transfer, what government interest statements do - and do not - tell you about a drug’s origins, why “march-in rights” were designed as a development backstop rather than a pricing tool, and how proposals to redirect royalties or restrict NIH-industry collaboration could disrupt the pipeline that turns early science into real-world therapies. Key Topics: * NIH’s Role in the Innovation Pipeline: How NIH funding de-risks foundational science, how industry and universities translate it, and why “NIH developed all drugs” is a misleading simplification. * Government Interest Statements: What the statement signals, why it is inconsistently surfaced across patents, and what large-scale reviews suggest about how often it appears in drug-related patent portfolios. * March-In Rights and Policy Misuse: The original purpose (anti-shelving and public health needs), how petitions are evaluated in practice, and why pricing-based efforts have not succeeded. * Mechanisms Supporting Translation: Why CRADAs and licensing structures matter for bringing technologies to market and for enabling NIH research with proprietary industry tools. * Forward Outlook: How royalty diversion or restricting partnerships could weaken incentives and capacity, and why the guests anticipate near-term disruption with longer-term consequences. Opinions expressed are those of the speakers. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.